Initially discovered as an antihistamine drug, repurposed as an EZH2 inhibitor by decreasing EZH2 expression and reducing the levels of H3K27me3 in breast cancer and prostate cancer cells. Also active in a triple-negative breast cancer murine model. Here, EZH2 is linked to triple-negative breast carcinoma.